Nachrichten zur Amicus Therapeutics Aktie

Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript

FOLD earnings call for the period ending March 31, 2021....…

AMICUS THERAPEUTICS, INC.: 10-Q Report

10-Q...…

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -8.70% and -7.47%, respectively, for the quarter ended March 2021. Do…

Recap: Amicus Therapeutics Q1 Earnings

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were…

Amicus Therapeutics posts pandemic hit Q1 earnings miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021

PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus…

Data Privacy and Cryptography Experts File Brief in Support of Census Bureau

BERKELEY, Calif., May 3, 2021 /PRNewswire/ -- Twenty leading experts, in data privacy and cryptography along with lawyers from Bondurant…

Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease

Amicus Therapeutics announces pre-BLA meeting with FDA for AT-GAA in Pompe disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus.io Expands Global Business Development Team, Appoints Tyler Voss as Chief Revenue Officer

CHARLOTTE, N.C., April 28, 2021 /PRNewswire/ -- Amicus.io, the fintech company on a mission to create a more generous world,…

Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host…

Insiderhandel: Chairman & CEO verkauft Aktien von Amicus Therapeutics im Wert von 222.086$

Crowley, John F. - Vorstand - Tag der Transaktion: 2021-04-15...…

Amicus Therapeutics (FOLD) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Amicus Therapeutics Stock Is Soaring Today

Investors cheered an analysts upgrade of the biotech stock....…

Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?

NEW YORK, April 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TV, PHUN, IBRX, FLXN, and FOLD. To…

Insiderhandel: Chief Operating Officer verkauft Aktien von Amicus Therapeutics im Wert von 105.505$

Campbell, Bradley L. - Vorstand - Tag der Transaktion: 2021-04-01...…

Insiderhandel: Aufsichtsrat kauft Aktien von Amicus Therapeutics im Wert von 15.000$

Whitman, Burke W. - Aufsichtsrat - Tag der Transaktion: 2021-04-01...…

Insiderhandel: Chairman & CEO verkauft Aktien von Amicus Therapeutics im Wert von 75.000$

Crowley, John F. - Vorstand - Tag der Transaktion: 2021-04-01...…

Assessing Amicus Therapeutics After Trial Results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Presents At MDA Clinical & Scientific Virtual Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Chairman & CEO verkauft Aktien von Amicus Therapeutics im Wert von 236.988$

Crowley, John F. - Vorstand - Tag der Transaktion: 2021-03-15...…

Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript

FOLD earnings call for the period ending March 31, 2021....…

AMICUS THERAPEUTICS, INC.: 10-K Report

10-K...…

Amicus Therapeutics FY 2020 top line up 43%

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics: Q4 Earnings Insights

Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per…

Amicus Therapeutics EPS misses by $0.08, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Earnings Preview for Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzingas ultimate preview for…

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

Amicus Therapeutics (FOLD) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Newell Brands, Amicus fall; HubSpot, Cognex rise

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Friday:...…

Artelo Biosciences leads healthcare gainers; Conformis and Amicus Therapeutics among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Reports Disappointing Tests Results for Pompe Disease Drug

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics downgraded to neutral from overweight at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out

Shares of Amicus Therapeutics Inc. were down 23.1% in premarket trading on Friday, the day after the company said…

Amicus Therapeutics cut to Neutral at Cantor citing PROPEL trial data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Presents At 17th Annual Virtual WORLDSymposium 2021 - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Updates on Phase 3 PROPEL Topline Results - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease

CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease.…

Amicus after announcing late-stage data for AT-GAA trial in Pompe disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus releases phase 3 results in Pompe disease trial

CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus announces early-stage interim data for AT-GTX-502 in Batten disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses...…

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021

Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease...…